Recombinant Human IL-1 RI Fc Chimera Protein, CF

When Recombinant Human IL-1 RI Fc Chimera Protein (Catalog # 11085-RI) is immobilized at 0.5 µg/mL (100 µL/well), Recombinant Human IL-1 beta /IL-1F2 (201-LB) binds with an ED50 of 0.600-5.40 ng/mL.

2 μg/lane of Recombinant Human IL‑1 RI Fc Chimera Protein (Catalog # 11085-RI) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 80-90 kDa and 160-180 kDa, respectively.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human IL-1 RI Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human IL-1 RI Fc Chimera (Catalog # 11085-RI) is immobilized at 0.5 µg/mL (100 µL/well), Recombinant Human IL-1 beta /IL-1F2 (Catalog # 201-LB) binds with an ED₅₀ of 0.600-5.40 ng/mL.
• Source: Human embryonic kidney cell, HEK293-derived human IL-1 RI protein
  

  Human IL-1 RI (Asp21-Lys336) Accession # P14778.1	IEGRMD	Human IgG1 Fc (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: P14778.1
• N-terminal Sequence: Asp21
• Structure / Form: Disulfide-linked Homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <1.0 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 63 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 80-90 kDa, under reducing conditions.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human IL-1 RI Fc Chimera Protein, CF

• CD121 antigen-like family member A
• CD121a antigen
• CD121a
• IL-1 RI
• IL1R
• IL1R1
• IL1RI
• IL-1RI
• IL1RT1
• IL-1RT1
• IL-1RT-1
• Interleukin 1 Receptor 1
• interleukin 1 receptor, type I
• interleukin receptor 1
• interleukin-1 receptor type 1
• p80

Background

The type I IL-1 receptor (IL-1 RI, designated IL-1 R1 and CD121a) is one of at least nine members of the IL-1 R family within the Toll/IL-1 R (TIR) superfamily (1 - 3). IL-1 RI is an 80 kDa type I transmembrane (TM) protein that binds the pleiotropic cytokines IL-1 alpha and IL-1 beta , plus the IL-1 receptor antagonist (IL-1 Ra). Signal transduction requires complex formation with the IL-1 R accessory protein (IL-1 R AcP/IL-1 R3), another type I TM protein (1, 2). This complex recruits the adaptor protein MyD88, to initiate signaling in the NF kappa B pathway (4, 5). Human IL-1 RI cDNA encodes a 569 amino acid (aa) protein that contains a 17 aa signal sequence, a 319 aa extracellular domain (ECD) with three C2-type Ig-like domains, a 20 aa TM domain and a 213 aa cytoplasmic region with a TIR domain. Within the ECD domain, human IL-1 RI shares 63% and 64% aa identity with mouse and rat IL-1 RI, respectively.  The role of IL-1 in inflammation is under several levels of control, including expression and activation of IL-1 alpha and IL-1 beta , expression of IL-1 RI and its accessory and adaptor proteins, and inhibitory IL-1 R isoforms and decoys (1 - 5). IL-1 RI is expressed predominantly by T cells, fibroblasts, and endothelial cells and mediates acute phase inflammatory responses including fever (1, 2, 5, 6).

1. Boraschi, D. & A. Tagliabue (2006) Vitam. Horm. 74:229.
2. Dinarello, C.A. (2002) Clin. Exp. Rheumatol. 20:S1.
3. Hart, R.P. et al. (1993) J. Neuroimmunol. 44:49.
4. Brikos, C. et al. (2007) Mol. Cell. Proteomics 6:1551.
5. Gasse, P. et al. (2007) J. Clin. Invest. 117:3786.
6. Ching, S. et al. (2007) J. Neurosci. 27:10476.

Bioinformatics

• Uniprot:
  • P14778.1()